kalshi Financials

FDA decision: DTX401 (pariglasgene brecaparvovec) by Ultragenyx Pharmaceutical (in 2026)

1 outcomes · Closes Jan 01, 2027 · 24h volume 489

Outcomes & current odds

a full approval or an accelerated approval
65%
489

Summary

SourceKalshi
Outcomes1
Total 24h volume489
ClosesJan 01, 2027
Leader
65% YES